In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model

Citation
F. Kanzawa et al., In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model, CANC CHEMOT, 43(5), 1999, pp. 353-363
Citations number
22
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
ISSN journal
0344-5704 → ACNP
Volume
43
Issue
5
Year of publication
1999
Pages
353 - 363
Database
ISI
SICI code
0344-5704(199905)43:5<353:IVIOAN>2.0.ZU;2-L
Abstract
Purpose: KRN5500 is a new derivative of spicamycin produced by Streptomyces alanosinicus and is known to have a wide range of antitumor activities aga inst human cancer cell lines. Because of its unique structure, this compoun d seems to have a different mode of action from other antitumor drugs and n onoverlapping toxicities. Therefore, KRN5500 is expected to be a suitable c andidate for combination chemotherapy. Methods: We investigated the effects of combinations of KRN5500 and other anticancer drugs on the growth of a h uman non-small-cell lung cancer cell line, PC14, using a revised three-dime nsional model. Results: Synergism was observed when KRN5500 and cisplatin w ere combined at concentrations in the ranges 0.005 to 0.25 mu g/ml and 0.02 5 to 0.25 mu g/ml, respectively. In combination with carboplatin, an analog of cisplatin, and etoposide, a marked synergistic interaction was also fou nd. Conclusion: These results suggest the usefulness of combinations of KRN 5500 with cisplatin, carboplatin or etoposide for chemotherapy for non-smal l-cell lung cancer.